

## Curriculum Vita



October-2016

### Personal Background:

**First Name:** Peyman

**Place of Birth:** Tehran, IR of Iran

**Marital Status:** Married

**Gender:** Male

**Home Address:** No 3, Yas4 Valley, Malekinasab Ave., Araghi Ave., Tehran, IRAN , 16639-38311

**Work Address:** Mofid Children Hospital, Shariati Aven., Tehran, IRAN, 15468-15514

**Work Website:** [www.pchd.sbm.ac.ir](http://www.pchd.sbm.ac.ir)

Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

**Tel:** +98 21 22265488, +98 21 22904536

**Tel(mobile) :** +98 912 396 8641

**Tel-fax (office) :** +98 21 22265488, +98 21 22904536

**e-mail :** [peshghi64@gmail.com](mailto:peshghi64@gmail.com)

**Cc :** [[p\\_eshghi@sbmu.ac.ir](mailto:p_eshghi@sbmu.ac.ir)]

## Educational Background:

**1983-1990:** MD. , Tehran Medical University

**1990-1993:** Pediatric specialty, Children Medical Center, Tehran Medical University, Tehran, Iran

**1994-1997:** Pediatric Hematology & Oncology subspecialty, Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran

## Employment and Related Professional Activities ,Membership and Affiliation:

### **Current situation and positions:**

- 1) N. Dehghan-Nateri, A. GHarebaghian,, K. Goudarzipour, **P. Eshghi**. the Fatty Acid Synthase is a Strong Predictor of Poor Prognosis and Contributes to Glucocorticoid Resistance in B-Cell Acute Lymphoblastic Leukemia. WCRJ 2016.
- 2) Kourosh Goudarzipour,Parinaz Alizadeh,Hesameddin Hoseini Tavasol,Reyhane Kazemi, Peyman Eshghi, Saeed Mojtahedzadeh  
A Comparison Between MRIT2 and NT-ProBNP in Early Detection of Heart Diseases in .  
Thalasemia Major Patients A Cross-Sectional Study
- 3) Prof. in pediatric Hematology & Oncology department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran,Iran :**May/2012-now**
- 4) **Founder and first Chair man of Iranian Society of Thrombosis and Hemostasis (IRSTH) since Jan-2016**
- 5) Head of pediatric Hematology & Oncology department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran : **May/2011-now**
- 6) Head attendant of Mofid Comprehensive Care Center for Children with Hemophilia: **2007-now**
- 7) **Research Deputy of “Pediatric Congenital Hematologic Disorders Research Center”:**  
**Aug/2012-now**
- 8) Board Member of Pediatric Hematology & Oncology discipline in MOH: **2007-now**
- 9) Board member of Iranian Pediatric Hematology & Oncology Society (IPHOS) :**2000-now**
- 10) Director of Strategic Planning Committee for Pediatric Hematology & Oncology of MOH.  
: **2007-now**
- 11) Member of hematologist counselors Committee in Deputy of health of MOH: **2005-now**
- 12) Member of Research committee of Iranian Blood Transfusion Organization: **2005-now**

## **Previous and other situations and positions:**

- 13)** Associate Prof. in Pediatric Hematology & Oncology, department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran: **2007- 2012**
- 14)** Assistant Prof. in pediatric Hematology & Oncology, department of Mofid Children Hospital, , Tehran, Iran: **2005-2007**
- 15)** Assistant Prof. in pediatric Hematology & Oncology; Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran; **1997-2005 ]**
- 16)** Counsellor to General Director of Iranian Blood Transfusion Organization: **2005-2010**
- 17)** President of Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran: **2000- 2004**
- 18)** Head of committee for Establishment of prenatal diagnosis center in Sistan & Balouchestan province(as the 5<sup>th</sup> national PND center in IRAN) and clinical attendant of this center: **2002-2005**
- 19)** Board member of Zahedan Medicine Council Organization: **2004-2006**
- 20)** Editorial Board Member of Scientific Journal of Iranian Blood Transfusion Organization (BLOOD): **2007-now**

And:

- Member of many other Scientific and Executive committees in Medical Universities, and Iranian Blood Transfusion Organization , regional, national and international congresses in IRAN: **1997-now**
- Speaker and coordinator in national workshops, congresses and CME seminars around the country and abroad **1997-now**
- Referee of many national medical journals: **2000-now**

## **Official Appreciations and Awards for Employment and Related Professional Activities:**

### **1- IRI Medicine Council Organization:**

- as the best Pediatric Hematologist and Oncologist in Iran: in **2005**

### **2- Ministry of health and medicine education:**

- for Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2005**
- for Diligently cooperation with National Thalassemia Prevention Program; **2008**

- for presentation an article about Medical Documents and improvement in medical education **2000**

### 3- Zahedan division of IRI Medicine Council Organization:

- as the best physician in S&B Province: **2001**

### 4- Zahedan Medical University:

- for Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2004**
- for especial respectability for patients and parents in Ali Asghar Children Hospital **2004**
- for successful educational efforts and obtaining the first national rank in resident training: **1999**
- for establishment of Rooming in service for mothers and neonates **1994**
- The best faculty member. **2001**

## Publications:

### Book Authoring:

- 1) **Comprehensive Management for Thalassemia in Iran** -2<sup>ND</sup> edition(in Persian); MOH publication (in press): 2016
- 2) Therapeutic Algorithms Of Musculoskeletal Complications Of Hemophilia(in Persian); Nashre Adiban publication: 2010
- 3) **Lymphadenopathy in children** (in Persian): [Pediatric Infectious Disease Research Center, Mofid children Hospital]; Donya-ye Taghzieh publication: 2009
- 4) **Comprehensive Management for hemophilia in Iran** (in Persian); MOH publication: 2008
- 5) **Comprehensive Management for Thalassemia in Iran** (in Persian); MOH publication: 2006
- 6) **Comprehensive textbook of Thalassemia in IRAN** (in Persian) Baghiat-allah University publication: 2005
- 7) **Textbook of Pediatrics** (in Persian); Shahid Beheshti University publication: 2005

### Published Articles in international journals:

1. kourosh Goudarzipour, Parinaz Alizadeh , Hesameddin Hoseini Tavassol, Reyhaneh Kazemi, Peyman Eshghi ,Saeed Mojtahedzadeh. A Comparison Between MRIT2 and NT-ProBNP in Early Detection of Heart Diseases in Thalassemia Maji

2. Peyvandi F, Mannucci Pier M., Garagiola Isabella, Amal El-Beshlawy, Mohsen Elalfy, M.D., Vijay Ramanan, **Eshghi P** and et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. *N Engl J Med* 2016; 374:2054-2064
3. Cheraghali A, Golestani M, **Eshghi P**, Rasekh H, Salamzadeh J, Imani A. Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran. *Iranian Journal of Pharmaceutical Sciences* (**ACCEPTANE** Manuscript ID: IJPS-1603-1189)
4. Golestani M, **Eshghi P**, Rasekh H, Cheraghali A, Salamzadeh J, Naderie M, Managhchi M, Hoorfar H, Toogeh GR, Imani A, Khodayari MT, Habibpanah B and Hantooshzadeh R. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. *Iranian Journal of Pharmaceutical Research* 2016; 15 (2): 669-677.
5. Tooge Gh, Abolghasemi H, **Eshghi P**, Managhchi M, Shaverdi-niasari M, Karimi K, Roostaei S, Emran N, Abdollahi A. Evaluation of Aryoseven Safety (recombinant activated factor VII) in patients with bleeding disorders (An observational post-marketing surveillance, study). *IJP* Articles in Press, Accepted Manuscript , Available Online from 11 May 2016
6. Gharibnaseri Z, Davari M, Cheraghali A, **Eshghi P**, Ravanbod R, Espandar R, Hantooshzadeh R. **Health care resource utilization and cost of care for haemophilia A and B patients in Iran.** *Transfus Apher Sci.* 2016 Feb; 54(1):122-6.
7. Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, **Eshghi P**, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Vaziri B, Kamyar K, Heshmat R<sup>4</sup>, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M. **A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.** *Clin Appl Thromb Hemost.* 2016 Mar;22(2):184-90
8. **Eshghi P**, Abolghasemi H, Malek F, Naderi M, Panahi Y, Habibpanah B, Fatohlahzadeh E, Gorji F. **A Prospective Crossover Triple-Blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto®) Versus Plasma Derived FVIII; A Pilot Study.** *IJBC* 2015; 7(4): 171-175
9. **Eshghi P** , Malek F , Madani F , Esfahani H . **Therapeutic Plasma Exchange in Pediatric Severe Immune Thrombocytopenia: A Case Report and Literature Review.** *IJBC* 2015; 7(3): 119-122
10. Faranoush M, Abolghasemi H, Toogeh G, Karimi M, **Eshghi P**, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M. **A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency.** *Clin Appl Thromb Hemost.* 2015 Nov; 21(8):724-8. doi: 10.1177/1076029614522545. Epub 2014 Mar 19.

11. Akbar Dorgalaleh, Majid Naderi, Maryam Sadat Hosseini, Shaban Alizadeh, Soudabeh Hosseini, Shadi Tabibian, Peyman Eshghi. Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. *Semin Thromb Hemost* 2015; 41(03): 323-329
12. Golestani M, **Eshghi P**, Rasekh H, Cheraghali A, Salamzadeh J, Imani A. Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients with Hemophilia and Inhibitors. *Iran Red Crescent Med J*. 2014 December; 16(12): e24551
13. Kajbafzadeh AM, Sabetkish S, Turchi A, Amirizadeh N, Afshar K, Abolghasemi H, Elmi A, Talab SS, **Eshghi P**, Mohseni MJ. The application of tissue-engineered preputial matrix and fibrin sealant for urethral reconstruction in rabbit model. *Int Urol Nephrol*. 2014 Mar 12. [Epub ahead of print]
14. Naderi, Dorgalaleh Majid, Tabibian Akbar, Shadi Eshghi, **Eshghi P**, Taregh Alizadeh, Shaban. Association Between Val34Leu Polymorphism and Risk of Umbilical Cord Bleeding in Severe Congenital Coagulation Factor XIII Deficiency in Southeast of Iran. *Gene Cell Tissue*. 2014; 1(1): e 18360.
15. **Eshghi P**, Jenabzadeh Alireza, Habibpanah Behnaz. Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital. *Iranian Journal of Blood & Cancer*. 2014; 6(3); 127-131.
16. Naderi M, Zarei T, Haghpanah Sezaneh, **Eshghi P**, Miri-Moghaddam E, Karimi M. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. 2014; 93(4): 693-697.
17. Naderi M, Dorgalaleh, Tabibian S, Alizadeh Sh, **Eshghi P**, Hosseini S. Effect of Consanguineous Marriages on the High Prevalence of Factor XIII Deficiency in Southeast of Iran. *Iranian journal of public health* 2013;
18. Goudarzi Pour K, **Eshghi P**, Aghakhani R, Askari Reza A, Nejat Mahmud P. Neuroblastoma Associated with Bilateral Ptosis: Report of a Rare Condition. *Iranian Journal of Blood and Cancer*. 2013; 6(1): 55-57.
19. **Eshghi P**, Jenabzade A, Habibpanah B. A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. *Hematology*. 2013 Oct 26. [Epub ahead of print]
20. The comparison of side effects and iron excretion in urine by two brands of deferoxamine( Desfonak® and Desferal® ) in major Thalassemia patients.
21. Alavi Samin, Malek Fatima, **Eshghi P**, Arzhangian Hossein. Autologous Platelet-Rich Plasma for Healing of an Oncologic Dehisced Wound. *APSP J Case Rep* 2013; 4(3):44
22. Dorgalaleh A , Naderi M, **Eshghi P**, Tabibian SH. Clinical manifestations of rare bleeding disorders in South East of Iran Hemophilia. 2013; 19(2):PO 382

23. Naderi M, Dorgalaleh A, Tabibian Sh, Alizadeh Sh, **Eshghi P**, Solaimani G. Current understanding in diagnosis and management of factor XIII deficiency. *Iran J Ped Hematol Oncol*. 2013;3(4):164-72.
24. Ziaee AM, Sarhangnejad R, Abolghasemi H, **Eshghi P**, Radfar MH, Ahanian A, Kardoust Parizi M, Amirizadeh N, Nouralizadeh A. Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study *Urology journal* (impact factor: 0.58). 01/2013; 10(3):999-1003.
25. Alzoebie A, Belhani M, **Eshghi P**, Kupesiz AO, Ozelo M, Pompa MT, Potgieter J, Smith M. Establishing a harmonized haemophilia registry for countries with developing health care systems. *Haemophilia*. 2013 Apr 17. doi: 10.1111/hae.12147. Epub 2013 Apr 17
26. Naderi M, **Eshghi P**, Cohan N, Haghpanah S, Karimi M. Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. *Haemophilia*. 2013 Mar 19. doi: 10.1111/hae.12112. [Epub ahead of print]
27. Alizadeh Z, Fazlollahi MR, Houshmand M, Maddah M, Chavoshzadeh Z, Hamidieh AA, Shamsian BS, **Eshghi P**, Bolandghamat Pour S, Sadaaie Jahromi H, Mansouri M, Movahedi M, Nayeypour M, Pourpak Z, Moin M. Different pattern of gene mutations in Iranian patients with severe congenital neutropenia (including 2 new mutations). *Iran J Allergy Asthma Immunol*. 2013 Mar;12(1):86-92. doi: 012.01/ijaai.869213.
28. Salehi T, Fazlollahi MR, Maddah M, Nayeypour M, Tabatabaei Yazdi M, Alizadeh Z, **Eshghi P**, Chavoshzadeh Z, Movahedi M, Hamidieh AA, Cheraghi T, Pourpak Z, Moin M. Prevention and Control Of Infections In Patients With Severe Congenital Neutropenia; A Follow Up Study. *Iranian Journal Of Allergy, Asthma And Immunology (Ijaai)*. 2012; 11(1): 51-56.
29. Naderi M, **Eshghi P**, Saneei Moghaddam E, Alizadeh S, Dorgalaleh A, Younesi MR, Khateb ZK. Safety of human blood products in rare bleeding disorders in southeast of Iran. *Haemophilia*. 2012 Dec 6. doi: 10.1111/hae.12068. [Epub ahead of print]
30. Salem K, **Eshghi P**. Dental health and oral health-related quality of life in children with congenital bleeding disorders. *Haemophilia* (2012), 1–6
31. Naderi M, **Eshghi P**, Cohan N, Miri-Moghaddam E, Yaghmaee M, Karimi M. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. *Haemophilia*. 2012 Sep;18(5):773-776. Epub 2012 Mar 28.
32. Cheraghali Abdol Majid, **Eshghi P**. Cost Assessment of Implementation of Immune Tolerance Induction in Iran. *Value in Health Regional Issues*. 1 ( 2 0 1 2 ) 5 4 – 5 8
33. Karimi M, Vafafar A, Haghpanah S, payandeh M, **Eshghi P**, Hoofar H, Afrasiabi A, Gerdabi J, Ardeshiri R, Menegatti M, Peyvandi F. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. *Haemophilia* (2012), 18, 211–215

34. **Eshghi P**, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran Clin Appl Thromb Hemost. 2011 Dec 6. [Epub ahead of print]
35. Alizadeh Z, Fazlollahi MR, **Eshghi P**, Hamidieh AA, Ghadami M, Pourpak Z. Iran Two Cases of Syndromic Neutropenia with a Report of Novel Mutation in G6PC3. J Allergy Asthma Immunol. 2011 Sep;10(3):227-30
36. **Eshghi P**, Farahmandinia Z. , Molavi M., Naderi M. , Jafroodi M. , Hoorfar H., Davari K., Azarkeivan A. , Keikhaie B. , Ansari S. , Arasteh M. : Efficacy and safety of Iranian made Deferasirox (osveral®) in Iranian major Thalassaemic Patients with transfusional iron overload :A One year Prospective Multicentric Open-Label Non-Comparative study. Daru, 2011, Vol. 19, No.3, 240-248
37. A.M. Cheraghali, **Eshghi P.**, H. Abolghasemi .Social consequences of infected haemophilia cases in the Islamic Republic of Iran. EMHJ, 2011, Vol. 17 ,No. 6 ,.552-556
38. Miri-Moghaddam E., Zadeh-Vakili A., Rouhani Z., Naderi M., **Eshghi P.**, Khazaei A. Feizabad6. Molecular basis and prenatal diagnosis of  $\beta$ -thalassaemia among Balouch population in Iran. Prenat Diagn (2011)
39. Alireza Foroutan, Fariba Beigzadeh, Mohammad Jafar Ghaempanah, **Eshghi P**, Naser Amirzadeh, PhD, Hamed Sianati, MD, Pooria Foroutan, MD. Efficacy of Autologous Fibrin Glue for Primary Pterygium Surgery with Conjunctival Autograft. Iranian Journal of Ophthalmology 2011;23(1):39-47
40. Kajbafzadeh AM, Abolghasemi H, **Eshghi P**, Alizadeh F, Elmi A, Shafaattalab S, Dianat S, Amirzadeh N, Mohseni MJ. Single-donor fibrin sealant for repair of urethrocutaneous fistulae following multiple hypospadias and epispadias repairs. J Pediatr Urol. 2010 Jul 14. [Epub ahead of print]
41. Eghbali Aziz, **Eshghi P**, Malek F, Abdollahpour Hengameh., Rezaei Nima. HAX1 mutation in an infant with severe congenital neutropenia. *The Turkish Journal of Pediatrics* 2010; 52: 81-84
42. **Eshghi P**, Mitra Mahdavi-Mazdeh, Mehran Karimi, Mohammad Aghighi. Haemophilia in the developing countries: the Iranian experience. Arch Med Sci 2010; 6, 1: 83-89
43. **Eshghi P**, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia. 2010 Mar;16(2):383-5.
44. Zadeh-Vakili A, **Eshghi P** Detection of a rare mutation in an Iranian family: codons 37/38/39 (7 bp deletion). Hemoglobin. 2009;33(6):523-7.



45. **Eshghi P**, Rashidi A, Zadeh-Vakili A, Miri-Moghadam E. Hematological phenotype of the IVS-I-5 (G > C) beta-thalassemia mutation and assessment of Iran's national screening criteria. Hemoglobin. 2008;32(5):440-5.
46. **Eshghi P.**, Zadeh-Vakili A, Rashidi A, Miri-Moghadam E. An unusually frequent beta-thalassemia mutation in an Iranian Province. Hemoglobin. 2008;32(4):387-92.
47. Trinh CH, Sh Elsayed W, **Eshghi P**, Miri-Moghaddam E, Zadeh-Vakili A, Markham AF, Anwar R. Molecular analysis of sixteen unrelated factor XIII A deficient families from south-east of Iran. Br J Haematol. 2008 Mar;140(5):581-4.
48. Sharifi-Mood B, **Eshghi P**, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J. 2007 Oct;28(10):1516-9.
49. Abolghasemi H, Amid A, Zeinali S, Radfar MH, **Eshghi P**, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H. Thalassemia in Iran: epidemiology, prevention, and management..J Pediatr Hematol Oncol. 2007 Apr;29(4):233-8
50. **Eshghi P**, Alavi S, Ghavami S, Rashidi A.. Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors.J Pediatr Hematol Oncol. 2007 Jan;29(1):5-8.
51. Ashena Zahra, Alavi Samin, Arzanian Mohammad Taghi., **Eshghi P**, Nail involvement in Langerhans cell Histiocytosis, Pediatric Hematology and Oncology, 24:45–51, 2007
52. Sharifi-Mood B, Smail Sanei-Moghaddam, Salehi M, **Eshghi P**, Soheila Khosravi and Manijeh Khalili. Viral Infection among Patients with Hemophilia in the Southeast of Iran, Journal of Medical Sciences 2006; 6(2): 225-228,
53. Karimi M. **Eshghi P.**, Unusual Lymphoblastic Leukemia/Lymphoma in Eastern Iran ,Indian Journal of Pediatrics, 2006; 73
54. **Eshghi P**, Abolghasemi Hassan, Esmail Sanei-Moghaddam, , Anwar Rashida, Jazebi Mohammad , Amid Ali, Fereydoun A. Ala, MD, FRCP, FRCPath ,, Factor XIII deficiency in southeast Iran, Haemophilia (2004), 10, 470–472.

#### **Published Articles in Iranian Journals:**

##### ***In Persian:***

- 1) Arzanian M.T., Shamsian B.Sh., Eshghi P., Kajiyazdi M., Alavi S., Nazari Sh.,Goudarzipour K. The clinical application of port A Cath in thehematology-oncology patients Sci J Iran Blood Transfus Organ 2015; 12(1): 85-99

- 2) Factor XIII deficiency in Sistan and Baluchistan province. Naderi M, Imani M, Alizadeh Sh, Dorgalaleh A, Tabibian Sh, **Eshghi P**, Sanei Moghaddam E, Mirimoghaddam E, Journal of Iranian Blood transfusion Organization Research Center 01/2013
- 3) Miri-Moghaddam E., Eshghi P., Sanei Moghaddam E., Hashemi SM. Prevalence of hemoglobinopathies in Sistan and Balouchistan province in the southeast of Iran. Sci J Iran Blood Transfus Organ 2013; 9(4): 406-413
- 4) Azarkeivan A, Arjangyan MH, Hajibeigi B, Afradi H, Aghaeepour M, Razjoo F, Sharifi SH, **Eshghi P**. Evaluation and Comparison of Washed RBCs by Closed and Open systems. Scientific Journal of Zanjan University; 1390; 19(75):66-76.
- 5) **Eshghi P**, Amin Asnafi A. Cerebral venous thrombosis in a child with Acute Lymphoblastic Leukemia and G20210A mutation of prothrombin gene during treatment. Sci J Iran Blood Transfus Org. 2011; 8(2): 143-148
- 6) Zahedpanah M, Azarkeivan A, Hajibeigi B, Ahmadinezhad M, **Eshghi P**, Tabatabaiee M.R. 1, Maghsudlu M. Coagulation inhibitors in Thalassemia. Sci J Iran Blood Transfus Org. 2010; 7(2): 78-84
- 7) Eshghi P.1,2(MD), Cheraghali A.M.1,3(PhD); Legal, social, and economic consequences of transfusion transmitted infections in Iran and in the world. **The Scientific Journal of Iranian Blood Transfusion Organization Research Center. Volume 6, Number 4 (Spring 2009)**
- 8) Noori N, **Eshghi P**, Shahramian I. Evaluation the effectiveness of combined iron chelation with deferipron and desferoxamine on the cardiac function in major beta thalassemic children in Zahedan,1383-1384. Tabib-e Shargh. Winter 88.No.11,Vol4.:35-40
- 9) Hashemi Teir A.1(MS), Amirizadeh N.1(PhD), **Eshghi P.**, Abolghasemi H.1,3(MD),Amani M.1(MS), Jabari A.1(BS), Ranjbaran R.1(MS), Mohammadi M.H.1(MS),Habibi Roudkenar M.1(PhD), Ali Balazadeh A. **Study of *in vitro* properties of fibrin sealant prepare from single donor plasma 4(BS. Sci J Iran Blood Transfus Org 2009; 6(3): 181-189**
- 10) Noori N, **Eshghi P**. Evaluation the effectiveness of captopril on the left heart function in major beta thalassemic children in Zahedan, 1381-1382. Scientific Medical Journal. Winter 2008; 6(4 (55)):492-498.

- 11) Shahriari HA, MD; Ghasemzadeh F, MD; **P. Eshghi**, MD; Masoomian B, MD. **Ocular Side Effects of Desferal® in Patients with βThalassemia**. Bina J Ophthalmol 2006; 11 (4): 519-523
- 12) **Eshghi Peyman**, Aliakbarian M, Taheribojd M.A, Davoudabadi H. **Classification of Arthropathies in Severe hemophilia type A, referred to Zahedan in 2003**. Medical Journal Of Mashad University of Medical Sciences, No.91, Vol49, Spring 2006
- 13) Abolghsemi H, **Eshghi Peyman**, Rahiminejad M.S, Hatami S. Evaluation and Cost-Effectiveness Analysis Of Prevention Program Of **Major Thalassemic** in **in Sistan and Baluchestan province** and Fars Province, HAKIM Winter. 2006; 8():85-14.
- 14) **Eshghi Peyman**, Rahimi M, Razaghi A; **Evaluation of effect of Family practice Consultation on Knowledge, Attitude and Practice of Major Thalassemic's Parents in the Prevention Program in Southeast IRAN**, Scientific Medical Journal of Ahwaz University of Medical Science , No.49 , Vol5, No2, Summer 2006.
- 15) **Eshghi Peyman** MD , Abolghasemi H. MD. , Sanei moghadam E. MD. , et al. , **Prevalence of factor XIII deficiency and abnormal clot solubility test in Sistan and Baluchestan province**, Hakim Research Journal , Vol.6 ,No.4 , Winter 2004
- 16) **Eshghi Peyman** MD, Razlansari Ali Akbar MD. , Roodbari Masood PHD . , **Prevalence of Impaired Oral Glucose Tolerance Test in Major Thalassemic Patients with and without Hepatitis C Virus Infection in Zahedan in 2001**, Scientific Medical Journal of Ahwaz University of Medical Science , No.38 ,December 2003.
- 17) **Eshghi Peyman** MD. , Sanei moghadam E. MD., Mirmasoudi M. MD, **Evaluation of Alloimmunization in major B.thalassemic patients in zahedan in 2001**, Journal of Mazandaran University of Medical Sciences , Vol.13 No.40 , Autumn 2003.
- 18) Miri-Moghadam E., Naroinejad.Mehrnaz , **Eshghi Peyman**, et al. **Molecular basis and Prenatal diagnosis of thalassemia in southeast Iran** . Journal Of Mazandaran University OF Medical Sciences, Fall 2003; 13():36-42.

**In English:**

- 1) **Eshghi P** , Jenabzadeh A , Habibpanah B . **Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital.** *IJBC 2014;6(3): 127-131*
- 2) **Eshghi P** , Khanali L , Abed-Saeedi J , Farahani H , Abdolah Gorgi F , Habib-Panah B , Tehrani Tarighat S , Alavi S ,Taslimi S . The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children. *IJBC 2013;2: 57-60*
- 3) **Peyman Eshghi**, Nader Cohan, Majid Naderi, Mehran Karimi. Factor XIII deficiency: a review of literature. *IJBC 2012;2: 85-91*
- 4) Eshghi P. Moradveisi B. **Frequency of Decreased Bone Mineral Density and Its Risk Factors during Childhood among Iranian Hemophilia Patients.** Iranian Journal Of Blood And Cancer 2011;4(1):
- 5) Peyman Eshghi,Kourosh Goudarzipour,Hoorieh Davoudabadi Farahani, Roxana Aghakhani Intra articular Injection of Rifampin in Iranian Children with Hemophilic Arthropathy. Iranian Journal of Blood and Cancer,Volume 3, Number 2. Winter 2011
- 6) Peyman Eshghi , Kourosh Goudarzi Pour and Roxana Aghakhani. Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis. Iranian Journal of Blood and Cancer,Volume 1, Number 4 (2009)
- 7) Aziz Eghbali, MD; Peyman Eshghi, MD; Fatemeh Malek, MD and Nima Rezaei, MD, PhD. Cardiac and Renal Malformations in a Patient with Sepsis and Severe Congenital Neutropenia. Iran J Pediatr, Vol 20 (No 2); Junr 2010
- 8) Peyman Eshghi,Hassan Abolghasemi.Selection Bias in reporting the prevalence of Transfusion Transmitted Infection Diseases inIranian Hemophiliacs.Iranian Journal of Pathology(2009)4 (4).197-198
- 9) A. Zadeh-Vakili, **P. Eshghi**, Gh. Rastegar Lari2. Efficiency of *BclI* Restriction Fragment Length Polymorphism for Detection of Hemophilia A Carriers in Sistan and Baluchestan Province, Southeast of Iran. *Iran J Med Sci* March 2008; Vol 33 No 1 33
- 10) **P. Eshghi**. Complications of Combined Treatment withDeferiprone and Desferrioxamine in Thalassemic Patients, *Iran J Med Sci*, 2007; 32(1)

 **Articles Presented in conferences:**

**1. Articles presented in 7<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders. Brussels, Belgium 26-28 February 2014**

- a. Severity of clinical manifestations based on plasma factor activity in rare bleeding disorders (poster)
- b. clinical manifestations and therapeutic response to recombinant factor VII in patients with glanzmann thrombasthenia (poster)
- c. Assessment the quality of life in children with factor XIII deficiency in southeast of Iran (poster)

**2. Articles presented 8<sup>th</sup> Congress of Iranian Society of Pediatric Blood and Cancer. Tehran, February 2014.**

- a. A self-controlled comparative clinical trial to explore the effectiveness of three topical haemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies
- b. A child with severe congenital factor VII Deficiency and factor VII alloantibody inhibitor

**3. Articles presented Von Willebrand Disease, Hemophilia and Rare Bleeding Disorders Congress , Kish, February 2014.**

- a. prophylaxis in Hemophilia
- b. Case Report
- c. Role of Fibrinogen in control of massive bleeding

**4. Articles presented 35<sup>th</sup> Dr. Gharib Congress, Tehran, May 2014.**

- a. Local Bleeding Inhibitors factor

**5. Articles presented in XXIV of the international society on thrombosis and hemostasis. Amsterdam, 29 June- 4 July 2013**

- a. Comparison of recombinant coagulation factor VII with NOVOSEVEN in patients with FVIII and IX deficiency with an inhibitor (ARYOSEVEN)
- b. Intracranial hemorrhage in factor XIII deficiency
- c. Effect of social factors on high prevalence of factor XIII deficiency in southeast Iran
- d. The Comparison of efficacy between recombinant activated factor VII ARYOSEVEN and NOVOSEVEN in patients with congenital factor VII deficiency

**6. Articles presented in TIF 2013:**

P. Eshghi, et al . The comparison of side effects and iron excretion in urine by two brands of deferoxamine ( Desfonak<sup>®</sup> and Desferal<sup>®</sup> ) in major Thalassemia patients. . OP13

**7. Articles presented in ISTH 2013:**

- a. Majid Naderi, Akbar Dorgalaleh, Peyman Eshghi, Shaban Alizadeh, Shadi Tabibian, Esmail Sanei Moghaddam. Effect of social factors on high prevalence of factor XIII deficiency in southeast Iran
  - b. Majid Naderi, Peyman Eshghi, Mehran Karimi, Akbar, Shadi Tabibian. Intracranial hemorrhage in factor XIII deficiency
  - c. The Comparison of efficacy between recombinant activated factor VII ARYOSEVEN and NOVOSEVEN in patients with congenital factor VII deficiency
  - d. Pregnancy and successful delivery of patients with FXIII deficiency on prophylaxis in Iran; report of 17 cases
- 
8. Articles presented in Opportunities and challenges in the clinical management of rare bleeding disorders in Iran & Lebanon, Beirut, 2013
- 
- a. Unmet needs in FXIII deficiency diagnosis
- 
9. Articles presented in Baxter & YOU partnering in coagulation management, Malta, 2013
- 
- a. Partnering in the management of patients with bleeding disorders
- 
10. Articles presented in Changing possibilities in hemophilia., Brussels, Belgium 24-25 February
- 
- a. Hemophilia Registry in Iran (oral)
- 
11. Articles presented in XXX International Congress of the World Federation of Hemophilia. Paris. 8-12 July 2012. Haemophilia (2012), 18 (Suppl. 3)
- 
- a. P. ESHGHI, B. MORADVEISI and M. ALAIEE! Frequency, Risk Factors and Consequences of Decreased Bone Mineral Density in Children with Hemophilia A and B. PO-WE-165
  - b. P. ESHGHI, K. SALEM! and A. RAJIS! " Oral health status and oral health-related quality of life in Iranian hemophilic pediatric patients PO-WE-076
  - c. A. CHERAGHALI \* and P. ESHGHI Cost Assessment of Implementation of ITI in Iran PO-MO-044
  - d. P. ESHGHI,\* A. JENABZADEH\* and B. HABIB PANAH! Five-year treatment report of hospitalized children with Glanzmann's thrombasthenia in a comprehensive hemophilia care centre (2006–2011) PO-WE-262
  - e. L. KHANALI, J. ABED-SAEEDI, H. FARAHANI, F. ABDOLLAH GORJI, B. HABIB-PANAH, S. TEHRANI TARIGHAT, S. ALAVI and P. ESHGHI. Quality of life of hemophilic children on prophylactic or on-demand treatment regimens in Iran PO-TU-211

- f. M. NADERI , P.ESHGHI and E. MIRI MOGHADDAM" Factor XIII deficiency in Sistan and Baluchestan of Iran PO-TU-259
  - g. Eshghi P. et al.Efficacy and safety of Osveral® -a new brand of Deferasirox- in Iranian major thalassemic patients with transfusional iron overload::A One year Prospective Multicentre Open-Label Non-Comparative study.12<sup>th</sup> International Conference on Thalassemia and The Hemoglobinopathies.11-14 MAY 2011.Antalya-Turkey
12. **Eshghi P. Local Hemostatic agents in Bleeding Disorders. 22-24 Dec 2010. 6<sup>th</sup> Iranian Congress of Pediatric emergency.3-7 Feb 2010 –Tehran -Iran**
  13. Recent progress in hemophilia care in Iran, International Education Thrombosis and Hemostasis symposium 15-16<sup>th</sup> April 2010 Shiraz
  14. **Coagulopathy in hematologic malignancies in children.6<sup>th</sup> congress of the SIOP ASIA March 3-5 2010- Kish**
    - a. Afradi H,,Arjangyan MH,,Azarkeivan A. ,Hajibeigi B.,Aghaeepour M.,Razjoo F., Safrifi SH., **Eshghi P.** Evaluation of new method for washed RBC compare with old system in point of health and leukoreduction. 5<sup>th</sup> National Conferenss of Iranian Pediatric Hematology & Oncology Society.13-15 May 2009-Ramsar – Iran
  15. Articles presented in National Conference on Health oriented Pediatrics.Yasooj 2009
    - a. Prevention Strategies for thalassemia.
  16. Articles presented in XIII Ophtalmology Congress.25-27 Nov 2008 Tehran Iran
    - a. AR. Foroutan,,P. Eshghi, P.bakhtiari,H. Sianati. Efficacy of autologous fibrin glue for the primary pterygium surgery with conjunctival autograft.
  17. Articles presented in 1<sup>st</sup> Iranian Seminar of Thrombosis and Hemostasis.May 14-15 2008, Mashad ,Iran
    - a. P.Eshghi. Von Willeberand Disease.
  18. Articles presented in the 11<sup>th</sup> international Conference on Thalassemia and Hemoglobinopathy . Singapore;8-11 October 2008
    - a. Eshghi p., Miri-Moghadam E., Sanei-Moghadam E., **Prevalence of B chain Hemoglobinopathies in south east of Iran(oral-F20)**
    - b. Eshghi p., Pahlavani H., Dolatshahi B..**Self concept and Depression in major beta thalassemic patients in south east of Iran(QOL-09)**

- c. Eshghi p., Rakhshani F., Ansari-Moghadam AR. **Analysis of intelligence quotient in patients with homozygous beta-thalassemia in South East of Iran(QOL-10)**
19. Articles presented in XXI Congress Of ISTH 6-12 July 2007, Geneva
- a. Rastegar, G. Tamadon, **P. Eshghi**, et al. Genetic Analysis of Patients with Factor XIII Deficiency in Iran: report of four novel mutations.
20. **Articles presented in Iranian Congress of Pediatric emergency. 3-7 Feb 2007 –Tehran –Iran**
- a. **Eshghi P. Therapeutic Plasma Exchange in Hematologic Disorders.**
21. Articles presented in **International Congress on Transfusion Medicine. 11-13 May 2007 Tehran-Iran**
- a. **Sharifi Mood B., Eshghi P., ET al. Concordance of Hepatitis C and B in Hemophilic patients in South East of Iran.**
22. **Articles presented in the XXVII<sup>th</sup> international Congress of the World Federation of Hemophilia Vancouver, Canada, 21-25 May 2006**
- a. A Zadeh-vakili, P Eshghi, G Rastegar Lari. **Efficiency of BclI restriction fragment length polymorphism for detection of haemophilia A carriers in Sistan and Balouchestan province in southeast of Iran.** Haemophilia (2006), 12, (Suppl. 2), page 12, (04 PO 73)
- b. P Eshghi, M. Jazebi, H. Hoorfar, M. Karimi, Z Badiee, M Yavari, M. Arasteh\_\_ and F Ala, **Multicentric screening of factor VIII inhibitor in 358 Hemophilia A patients in IRAN 2005.** Haemophilia (2006), 12, (Suppl. 2), page 61, 14 PO 382
23. **Articles presented in the 10<sup>th</sup> international Conference on Thalassemia and Hemoglobinopathy . Dubai-UAE ,Jan. 7-10 2006:**
- a. **Peyman Eshghi MD., maasoumeh Fadaie MD., Esmail sani moghadam MD. Hepatitis C virus infection status and blood safety in 454 major b thalassemic patients in south east of IRAN in 2005**
- b. **Peyman Eshghi MD. , Ebrahim M. Mogadam MsC., Azita Z. Vakili PhD. Hematological values in heterozygotes for the IVS 1-5 G → C ( b°) as the most common type of beta thalassemia mutation in south east of IRAN**
- c. **Peyman Eshghi MD., Hossein-ali Shahriari MD. Evaluation of ocular finding in B thalassemia under Treatment with desferal**
- d. **Peyman Eshghi M.D., Shahab-al-din Mashaie MD. Complications and Compliance to Deferiprone in 33 Beta thalassemic Patients on Combination therapy with L<sub>1</sub> and Desferal in Zahedan 2003-2005**
- e. Eshghi p., Soleimani G., Tehrani H. Complication and efficacy of combination therapy with Alpha Interferon and Ribavirin for Hepatitis C in Thalassemic Patients in Zahedan. 4th Congress of Iranian Pediatric Hematology & Oncology Society. 7-9 September 2006 , Kerman , Iran-Ramsar –Iran



24. Articles presented in XX Congress Of ISTH 6-12 Aug. 2005, Sydney, Australia
- a. **High Sensitivity Of Monochloroacetic Acid 1% Clot Lysis Test For Diagnosis Of Severe FXIII Deficiency,**
25. Articles presented in 27<sup>TH</sup> International congress of the World Federation of Hemophilia, **October 17 to 21, 2004 Bangkok, Thailand**
- a. **Eshghi P., Hassan Abolghasemi, Esmail Sanei-Moghaddam, Rashida Anwar, Mohammad Jazebi, MSc, Ali Amid, Fereydoun A. Ala, High prevalence of Factor XIII deficiency in southeast Iran.**
26. Articles presented in 2<sup>nd</sup> congress of Iranian Pediatric Hematology & Oncology Society (IPHOS), Kish April 28-30, 2004 (oral)
- a. **Eshghi P., Hematologic and electrophoretic phenotype of 116 carriers of beta thalassemia with IVS I-V mutation in S& B province of IRAN.**
  - b. **Eshghi P., Miri-moghadam E. Naroi-nejad M. Msc., Epidemiological report of PND on thalassemia in S& B province of IRAN**
27. Articles presented in 2<sup>nd</sup> congress of Iranian Pediatric Hematology & Oncology Society (IPHOS), Kish April 28-30, 2004(oral)
28. Articles presented in 4<sup>th</sup> national Iranian congress of Hematology and Oncology, Mashad, June 24-26 2004
- a. **Eshghi P, Epidemiological changes in childhood acute leukemia in Sistan & Baloochestan province during 2003-2004. (poster)**
  - b. **Eshghi P, Karimi M. MD., Unusual presentation of T cell Acute Lymphoblastic Leukemia/Lymphoma with huge enlargement of mandibula and maxilla in a child (oral)**
29. Articles presented in the 9<sup>th</sup> international Conference on Thalassemia and Hemoglobinopathy. Palermo-Italy, October 15-19 2003:
- a. **Eshghi Peyman, Razlansari Ali Akbar MD., Roodbari Masood PHD., Prevalence of Impaired Oral Glucose Tolerance Test in Major Thalassemic Patients with and without Hepatitis C Virus Infection in Zahedan in 2001(oral-70)**
  - b. **Abolghasemi MD., Eshghi P. MD., Evaluation of diagnosis and prevention program for Thalassemia in Sistan & Baloochestan province of IRAN in 1999-2002(oral-24)**
  - c. **Eshghi Peyman MD, Rahimi M. MD., Razaghi A. Msc., Evaluation of family practice consultation on knowledge, attitude and practice of major beta thalassemic's parents as an effective prevention program in south-east of IRAN (Zahedan -2001)(P77)**

- d. Razaghi A. Msc, **Eshghi Peyman MD** , Zabolizadeh Z. , **Assessment the knowledge, attitude and practice of major beta thallemic`s parents about thallemia-Zahedan 1998 (P 56)**
  - e. Abolghasemi MD. , Hatami S ., **Eshghi P. MD.**, **The causes of major thallemia birth after thallemia prevention progam in Sistan & Baloochestan province of IRAN IN 2003 (P82)**
  - f. Miri-moghadam E. Msc., Naroi-nejad M. Msc., **Eshghi P. MD.** , **Prenatal diagnosis of beta thallemia in southeast of IRAN 2002-2004 (P84)**
  - g. Noori n N. MD., **Eshghi P. MD.** , Aliakbarian M. MD., **Echocardiographic finding in major beta thallemic patients in Zahedan-IRAN 2000 (P156)**
  - h. Davood-abai Farahani H. MD., **Eshghi P. MD.** , **Evaluation of compliance to iron chelation therapy with desferoxamine in major thallemic children in Zahedan-IRAN 2001 (P164)**
30. Articles presented in 1<sup>st</sup> international symposium of hemostasis & thrombosis. Shiraz,2003
- a. **Eshghi P. Congenital deficiency of fibrin stabilizing factor in 44 cases in S& B province of IRAN. (oral)**
31. Articles presented in 1<sup>st</sup> congress of Iranian Pediatric Hematology & Oncology Society (IPHOS). Tehran, May 2-4, 2002
- a. Rakhshani F, **Eshghi P. MD., et al. Evaluation of IQ in major beta thallemic children in Zahedan in 2001 . (post.)**
32. Articles presented in 1<sup>st</sup> congress of Iranian Pediatric Hematology & Oncology Society (IPHOS). Tehran ,May 2-4, 2002
- a. Fattahi F. MD., **Eshghi P. MD.,et al. Endocrin problems in major beta thallemic children in Zahedan in 2001. (oral)**
33. Articles presented in 1<sup>st</sup> congress of Iranian Pediatric Hematology & Oncology Society (IPHOS) . Tehran ,May 2-4, 2002
- a. Pahlevani H. Msc., Dolatshahi B. MD., **Eshghi P. MD., . Evaluation of Self concept and depression in major beta thallemic children in Zahedan in 2001. (Oral)**
34. Articles presented in 8<sup>th</sup> international Conference on Thallemia and Hemoglobinopathy. Athens, Greece , October 18-21 ,2001.(P87)
- a. **Eshghi P, Nazari S. Prevalence of sensory-neural and conductive hearing loss in transfusion dependent thallemic children in Zahedan-IRAN 2001.**
35. Articles presented in Congress of nephrology ,Zahedan-IRAN ,March 11-13 2001
- a. **Eshghi P. MD.,Correlation between transfusion protocole and urate crystaluria in major beta thallemic children in Zahedan in 1998.**
36. Articles presented in 13<sup>th</sup> international congress of pediatrics. Tehran ,October 5-10, 2001

- a. **Eshghi P., Ghavami S. Correlation between serum zinc and height of major beta thalassemic children in Zahedan in 2000 .**
- 37. Articles presented in Iranian society of pediatrics congress on Pediatrics updates ,Tehran ,Dec20-24,1997
  - a. **Arzanian M., Eshghi P., Cytogenetic characteristic of acute leukemia in 50 children in mofid children hospital in 1997.**

## **Researches; Scientific projects and Dissertations:**

### **International Multicentre Studies (As Main Investigator in IRAN):**

- 1- **(3WINTERS-IPS):Type 3 Von Willebrand International Registries Inhibitor Prospective Study - Prospective, Multicentre, International,Non-interventional 5-year Clinical Study .Promoted by AB BONOMI Foundation,a NO-profit Organization with funds obtained from unrestricted grants of Five Companies-in process**
- 2- **SIPPET( Survey of Inhibitors in Plasma-Product Exposed Toddlers) Study, and independent ,multicentre, international ,prospective ,controlled ,randomized,open labeled clinical trial.Promoted by Fondazione Angelo Bianchi Bonomi in more than 60 centers around the world –in process**
- 3- **SMART-7: Prospective Observational Study on NovoSeven® RoomTemperature Stable (VII25) in Patients with Haemophilia A or B.an international study. Promoted and sponsored by Novo Nordisk Company**
- 4- **TARGET: study:An observational sTudy to Assess the feasibility of combining data from patient ReGistries in countries with developing health care systems to EvaluaTe Haemophilia management. Promoted and sponsored by Novo Nordisk Company**

### **National and multicenter projects and clinical trials as the Main Researcher (ordered ,supervised or Granted by Ministry of Health of IRAN)**

1. **National Registry of congenital bleeding disorders In Iran. National project ,ordered and supervised by MOH(finished)**

2. **Randomized triple-blind controlled trial: Urine Iron excretion following Desfonak vs. Desferal administration in major thalassemic patients: A Multicenteric randomized triple-blind controlled clinical study (finished and going to be published)**
3. **Health Technology assessment of Implementation of Immune Tolerance Induction in hemophilia A patients with high titer inhibitor in Iran: a HTA study under supervision of National Health Research Institute).(finished and published)**
4. **Comparative cross over Triple blind Clinical Trial on safety and efficacy between Iranian produced Recombinant Factor Eight and Plasma derived Factor Eight in previous treated hemophilic patients in Iran (finished)**
5. **Efficacy and safety of Osveral® (Deferasirox) in Iranian major Thalassemic Patients with transfusional iron overload: :A One year Prospective Multicentric Open-Label Non-Comparative stud).(finished and published)**

#### **Other projects and clinical trials as the Main Researcher**

1. Comparing the cost-effectiveness of two alternative bypassing agents for patients with hemophilia A complicated by an inhibitor in Iran.(finished)
  2. Oral health status and oral health–related quality of life in Iranian hemophilic pediatric patients : Research project & dissertation of Salem K.. MD.(finished and going to be published)
  3. Frequency, Risk Factors and Consequences of Decreased Bone Mineral Density in Children with Hemophilia A and B. . Research project & dissertation of Moradveisi B. MD.(finished and going to be published)
  4. Safety , efficacy and cost of implementation of Immune Tolerance Induction in hemophilia A patients with high titer inhibitor in Iran :A Multicentric observational clinical study (in process)
1. Experience of single donor plasma produced fibrin sealant in reconstructive surgery of urethral fistula by preputial acellular matrix graft in rabbit: Scientific project of Iranian Blood Transfusion Organization Research Center & Pediatric Urology Research Center of Tehran University of Medical Sciences

2. In vitro characteristics and efficacy of fibrin sealant produced from from single donor human plasma in blood bank -2008 : Scientific project of Iranian Blood Transfusion Organization Research Center; MsC dissertation of Hashemi A.
3. Efficacy and Complications of Autologous Fibrin Glue for Primary Pterygium surgery by conjunctival Autograft-2008.: clinical trial study ; with collaboration between Iran Medical University & IBTO, Ophthalmology dissertation of Sianaty H. MD.
4. A Prospective assessment of outcomes of applying autologous fibrin sealant in tubless percutaneous nephrolithotomy (PCNL) in Shaheed Labbafinejad Hospital from 2007 to 2008 : clinical trial study ; with collaboration between Urologic Disease Research Center in Labafi-nejad Hospital & IBTO
5. Screening of Hemoglobinopathy in S&B province of IRAN , 2004 ,( Research project with collaboration between :Zahedan Medical University , Zahedan Division of Iranian Transfusion Organization
6. Multicentric screening of factor VIII inhibitor in Hemophilia A patients in IRAN 2005 (Scientific project with collaboration between 6 Medical Universities ,and Iranian Hemophilia Society. Sponsored by Novo- Nordisk company)
7. Evaluation of diagnosis and prevention program for Thalassemia in Sistan & Baloochestan province of IRAN in1999-2002 ,( Research project with collaboration between Ministry of Health and Medical education of IRI & Iranian Pediatric Hematology & Oncology Society (IPHOS) )
8. Radiological and clinical classification of joint status of severe hemophilia A patients according to Peterson& Gilbert criteria in Zahedan in 2002- 2003 ( Pediatric dissertation of Ali-Akbarian M. MD. .-Zahedan Medical University)
9. Evaluation of efficacy and complication of combination therapy with deferipon and desferal in cardiomyopathic major beta thalassemic patients in Zahedan ( Pediatric dissertation of Dashti M.. MD.-Zahedan Medical University)
10. Hematologic and electrophoretic phenotype of 116 carriers of beta thalassemia with IVS I-V mutation in S& B province of IRAN , 2002-2003 (MD. Thesis of Kamalinia H.-Zahedan Medical University)
11. Evaluation of efficacy and complication of combination therapy with ribavirin and alpha-interferon 2b for HCV in major beta thalassemic children and patients under 18 years old in Zahedan ( Pediatric dissertation of Tehrani H. MD.-Zahedan Medical University)

12. Prevalence of Impaired Oral Glucose Tolerance Test in Major Thalassemic Patients with and without Hepatitis C Virus Infection in Zahedan in 2001, ( Pediatric dissertation of Razlansari A. MD. .-Zahedan Medical University)
13. Evaluation of Alloimmunization in major B.thalassemic patients in zahedan in 2001, ( Pediatric dissertation of Mirmasoudi M. MD. .-Zahedan Medical University)
14. Comparison of sensitivity and specificity of hematologic index testes in screening of beta thalassemia minor in the family of major beta thalassemia patients in Zahedan in 1999 ( Pediatric dissertation of Ghasemi K. MD. .-Zahedan Medical University)
15. Assessment the knowledge, attitude and practice of major beta thalassemic`s parents about thalassemia-Zahedan 1998 (MD. Thesis of Bozorgh-zade S.-Zahedan Medical University)
16. Correlation between transfusion protocole and urate crystaluria in major beta thalassemic children in Zahedan in 1998 , (MD. Thesis of Ghorbani H.-Zahedan Medical University)
17. Evaluation of family practice consultation on knowledge, attitude and practice of major beta thalassemic`s parents as an effective prevention program in south –east of IRAN (Zahedan -2001)( Research project with collaboration between Ministry of Health and Medical education of IRI , Zahedan Medical University)
18. Correlation between serum zinc and height of major beta thalassemic children in Zahedan in 2000 , (Research project & Pediatric dissertation of Hadizadeh F... MD.- Zahedan Medical University)
19. Evaluation of inhibitor titer in Hemophilia A and B patients in Zahedan in 1998-1999 ( Pediatric dissertation of Safaie H. MD.-Zahedan Medical University)

 **As The Main Colleague, Consultant or Advisor of the Research:**

- 1- Comparison of Quality Of Life in children with hemophilia with and without prophylactic treatment in Tehran-1388 , Research project & MsC dissertation of Khan-Ali L. . supervised by: Abed Saeidi J.,Eshghi P.,Farahani H.

- 2- Comparative study between two methods for RBC washing in Blood Bank of Zafar Clinic considering their efficacy ; quality of blood product and adverse effects on environmental pollution-2006-2007 . Research project supervised by: Arzhangian M. , Iranian Blood Transfusion Organization
- 3- Evaluation of prevalence of thrombophilic factors in Thalassemic patients in Zafar Clinic-2007. Research project & MSc dissertation of Zahedpanah M. . supervised by: Azarkeivan A.
- 4- Evaluation of ocular finding in B thalassemia under Treatment with desferal. 1383, Research project & dissertation of Masoumian B. supervised by: Shahriari H. MD. , , covered by Zahedan Medical University
- 5- Evaluation of tubular and glomerular dysfunction of kidney in major beta thalassemic children in Zahedan-2004 Research project supervised by: Sadeghi S. MD. , Zahedan Medical University
- 6- Evaluation of Self concept and depression in major beta thalassemic children in Zahedan in 2001 Research project supervised by: Pahlevani H. Msc. , Zahedan Medical University
- 7- Incidence of mental health status in parents of cancer children in Zahedan -1383 Research project supervised by: Sajadi A. MD. , , Zahedan Medical University
- 8- Evaluation of IQ in major beta thalassemic children in Zahedan in 2001 , Research project supervised by: Rakhshani F. PhD. Zahedan Medical University
- 9- Endocrin problems in major beta thalassemic children in Zahedan in 2001. Research project supervised by: Fatahi F. MD. , Zahedan Medical University
- 10- Echocardiographic assessment of major B.thalassemic patients in Zahedan based on PEP/ET in 2000-2001 Research project supervised by: Noori N. MD. , Zahedan Medical University
- 11- Prevalence of sensory-neural and conductive hearing loss in transfusion dependent thalassemic children in Zahedan-IRAN 2001 Research project supervised by: Nazari S. MD. , Zahedan Medical University

